An update on current and prospective immunotherapies for chronic lymphocytic leukemia

被引：0

作者：

Emole, Josephine N. ^{[1
]}

Locke, Frederick L. ^{[2
]}

Pinilla-Ibarz, Javier ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 04期

关键词：

bispecific T-cell engager; chimeric antigen receptor; chronic lymphocytic leukemia; immunotherapy; monoclonal antibody; STEM-CELL TRANSPLANTATION; PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; TUMOR-ASSOCIATED ANTIGENS; PHASE-II TRIAL; TERM-FOLLOW-UP; T-CELLS; INITIAL THERAPY; CD20; ANTIGEN; OPEN-LABEL;

D O I：

10.2217/IMT.15.14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic lymphocytic leukemia (CLL) is the most common leukemia. Combined agent chemotherapy is the current standard front-line treatment for physically fit patients with CLL. Use of chemotherapy can be complicated by significant toxicity, especially in patients with advanced age or comorbid conditions. Moreover, patients may relapse and become refractory to further chemotherapy. Immunotherapy targets the aberrant immunological processes in CLL without the toxicity of chemotherapy. Immunotherapeutic strategies can also be combined with chemotherapy to improve response rates in this incurable disease. In this review, we evaluate current and future immune-based options in the treatment of CLL.

引用

页码：455 / 466

页数：12

共 50 条

[31] Update on risk-stratified management for chronic lymphocytic leukemia
Zent, Clive S.
Call, Timothy G.
Hogan, William J.
Shanafelt, Tait D.
Kay, Neil E.
[J]. LEUKEMIA & LYMPHOMA, 2006, 47 (09) : 1738 - 1746
[32] ASH Update 2013: Chronic lymphocytic leukemia and indolent lymphoma
Steurer M.
[J]. memo - Magazine of European Medical Oncology, 2014, 7 (3) : 141 - 143
[33] A CLINICAL UPDATE ON CHRONIC LYMPHOCYTIC-LEUKEMIA .2. CRITICAL ANALYSIS OF CURRENT CHEMOTHERAPEUTIC MODALITIES
TEFFERI, A
PHYLIKY, RL
[J]. MAYO CLINIC PROCEEDINGS, 1992, 67 (05) : 457 - 461
[34] Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia
Wendtner, Clemens-Martin
Gregor, Michael
[J]. LEUKEMIA & LYMPHOMA, 2018, 59 (02) : 300 - 310
[35] Chronic lymphocytic leukemia: recent progress and current challenges
Woyach, Jennifer A.
Johnson, Amy J.
Byrd, John C.
[J]. SEMINARS IN ONCOLOGY, 2016, 43 (02) : 199 - 200
[36] Current approach to diagnosis and management of chronic lymphocytic leukemia
Shanafelt, TD
Call, TG
[J]. MAYO CLINIC PROCEEDINGS, 2004, 79 (03) : 388 - 398
[37] Atypical Chronic Lymphocytic Leukemia-The Current Status
Robak, Tadeusz
Krawczynska, Anna
Cebula-Obrzut, Barbara
Urbaniak, Marta
Iskierka-Jazdzewska, Elzbieta
Robak, Pawel
[J]. CANCERS, 2023, 15 (18)
[38] Interdisciplinary approach to the current management of chronic lymphocytic leukemia
Robert, Szasz
Arpad, Illes
[J]. ORVOSI HETILAP, 2021, 162 (09) : 336 - 343
[39] Current and future treatment strategies in chronic lymphocytic leukemia
Krish Patel
John M. Pagel
[J]. Journal of Hematology & Oncology, 14
[40] Current treatment management of chronic lymphocytic leukemia (CLL)
Eichhorst, B.
[J]. ONKOLOGIE, 2012, 35 : 2 - 2

← 1 2 3 4 5 →